药品集团采购组织的市场竞争效应——基于我国GPO试点的理论分析

发布时间：2018-04-12 10:30

  本文选题：集团采购组织 + 产品多元　； 参考：《中山大学学报(社会科学版)》2017年06期

【摘要】：中国医药卫生体制改革中"看病难,看病贵"的问题依然存在,医疗保险基金支出压力巨大。本文通过理论建模,发现药品集团采购组织(GPO)通过第三方的集中竞价模式,提高采购效率,降低药品价格,对于降低医疗费用具有直接正向作用。同时,集团采购的组织形式对于缓解中国医疗体系中存在的公立医院垄断,实现"医药分开"具有一定的辅助作用。另外,药品GPO作为具有垄断势力的买方,在药品采购时的非中立性可能会损害上游医药企业的公平竞争,长此以往甚至会损害药品的多样性;过分追求降价的不合理措施反而会导致潜在垄断与劣质服务。因此,我国在进行GPO改革时,一定要注意竞争效应,可以在GPO层面引入竞争,防止GPO对公平竞争市场秩序的破坏。
[Abstract]:In the reform of Chinese medical and health system, the problem of "difficult and expensive to see a doctor" still exists, and the expenditure of medical insurance fund is under great pressure.Through theoretical modeling, it is found that GPOs, through the centralized bidding mode of the third party, can improve the purchasing efficiency and reduce the drug price, which has a direct positive effect on reducing the medical cost.At the same time, the organizational form of group procurement is helpful to alleviate the monopoly of public hospitals in Chinese medical system and to realize the separation of medicine and medicine.In addition, as a buyer with monopoly power, the non-neutrality of drug GPO in drug procurement may damage the fair competition of upstream pharmaceutical enterprises, and even damage the diversity of drugs in the long run.Excessive pursuit of unreasonable measures to reduce prices will lead to potential monopolies and poor quality services.Therefore, our country must pay attention to the competition effect when carrying on the GPO reform, may introduce the competition in the GPO level, prevents the GPO to the fair competition market order destruction.
【作者单位】： 中国人民大学汉青经济与金融高级研究院、国家发展与战略研究院反垄断与竞争政策研究中心;中国人民大学汉青经济与金融高级研究院;
【基金】：国家自然科学基金(71773129/71273270) 国家“万人计划”青年拔尖人才支持计划(W02070290) 青年长江学者奖励计划(Q2016037) 霍英东教育基金(141082) 中国人民大学科学研究基金(中央高校基本科研业务费专项资金资助,14XNI006/17XNH030)
【分类号】：F274;F426.72;R197.1
，

本文编号：1739354